Katherine Ruffner, MD

Dr. Ruffner has served as our Vice President, Clinical Development since February 2020. Prior to joining us, she was a consulting Global Clinical Lead for Lumoxiti at Acerta/Astra Zeneca from Februrary 2019 to February 2020. From April 2008 to February 2019, Dr. Ruffner held multiple clinical development positions within the field of oncology, most recently as Vice President, Clinical Development for CTI Biopharma. She holds a B.S. in Biology from Duke University and an M.D. from the University of Tennessee. Dr. Ruffner completed her internal medicine residency training at the University of Michigan and her oncology fellowship training at Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center.